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After the ﬁrst reports about a protective effect on coronary heart disease (CHD) published
more than 40years ago, wide interest in the therapeutic use of n 3 polyunsaturated fatty
acids (n 3 PUFA) aroused. Since then, many studies and meta-analyses have reported a
signiﬁcantly reduced risk of CHD and CV death due to ﬁsh and n 3 PUFA intake. Some
of the overviews reported a signiﬁcant reduction of risk of sudden cardiac death, all-cause
death, and nonfatal CV events. On the other side, recent clinical trials had mixed ﬁndings,
raising concern about the consistency of the evidence on n 3 PUFA.We critically reviewed
recent large clinical trials reporting data on the antiarrhythmic effects of n 3 PUFA in dif-
ferent clinical settings, i.e., patients with CHD, heart failure, with implantable cardioverter
deﬁbrillator, and at risk of atrial ﬁbrillation, in order to summarize the results which are
available up to date and possibly give “substantiated” fuel to the debate on the conﬂicting
results of n 3 PUFA.  
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INTRODUCTION
After the ﬁrst report about a protective effect on coronary heart
disease (CHD) published more than 40years ago, wide interest
in the therapeutic use of n 3 polyunsaturated fatty acids (n 3
PUFA) aroused (Bang et al., 1971; Bang and Dyerberg, 1972).
Since then, many studies have been performed, increasing our
knowledge on the cardiovascular (CV) effects of n 3 PUFA.Var-
ious meta-analyses have reported a signiﬁcantly reduced risk of
CV events,primarily due to reduction of CHD and CV death due
to ﬁsh and n 3 PUFA intake (He et al., 2004; Leon et al., 2008;
MarikandVaron,2009;Menteetal.,2009).Someof theoverviews
reported a signiﬁcant reduction of risk of sudden cardiac death
(SCD; Leon et al., 2008; Marik and Varon, 2009), all-cause death
(Marik and Varon, 2009), and non-fatal CV events (Marik and
Varon, 2009). However, several questions remain open to date,
e.g.,themechanismsaccountingforthebeneﬁtobservedinclinical
studies as well as a possible heterogeneity of the effect in different
populations. On the other side, recent clinical trials had mixed
ﬁndings,raising concern about the consistency of the evidence on
n 3 PUFA.
Among the many physiological effects which n 3 PUFA are
supposed to have,the antiarrhythmic effect is the most interesting
one but is challenging to be documented in humans because of
the absence of reliable physiological measures or biomarkers to
quantify the antiarrhythmic potential of n 3 PUFA on SCD.
We critically reviewed recent large clinical trials reporting data
on the antiarrhythmic effects of n 3 PUFA in different clinical
settings,i.e.,patients with CHD (Marchioli et al.,2002;Yokoyama
et al., 2007; Rauch et al., 2010), heart failure (HF; Tavazzi et al.,
2008),withimplantablecardioverterdeﬁbrillator(ICD;Leaf etal.,
2005; Raitt et al., 2005; Brouwer et al., 2006), and at risk of atrial
ﬁbrillation (AF; Calo et al.,2005; Kowey et al.,2010; Nodari et al.,
2011), in order to summarize the results which are available up
to date and possibly give“substantiated”fuel to the debate on the
conﬂicting results of n 3 PUFA.
CORONARY HEART DISEASE
The ﬁrst intervention study suggesting an antiarrhythmic effect
of n 3 PUFA was the Diet and Reinfarction Trial (DART) study
carried out on 1989 (Burr et al., 1989). In 2033 post-myocardial
infarction (MI) men, those advised to eat fat ﬁsh two to three
times a week had a signiﬁcant 29% reduction in fatal MI com-
paredtothosenotadvisedso.Thisbeneﬁtappearedearlyafterthe
start of the trial and was hypothesized to be due to a reduction of
sudden death. Some years later,a decreased mortality and sudden
deathwereobservedinpost-MIpatientsreceivingaMediterranean
alpha-linolenic acid (ALA)-rich diet (de Lorgeril et al., 1994). In
another trial, patients with suspected MI and receiving ﬁsh oil
(2g n 3 PUFA daily) or mustard seed oil (containing 2.9g of
ALA per day) experienced fewer sudden deaths than the placebo
group(Singhetal.,1997).Ananalysisof theUSPhysician’sHealth
Study, a prospective study on 20,551 male physician followed for
upto11years,showedthatﬁshconsumptiononceperweekwas
associated with a 52% reduction in the risk of SCD as compared
with men with lower ﬁsh intake (Albert et al., 1998). Later, a new
report from this study showed an inverse relationship between
blood levels of long chain n 3 PUFA and risk of SCD (Albert
et al.,2002).
The strongest evidence suggesting an antiarrhythmic effect of
n 3 PUFA was provided by GISSI-Prevenzione, an open-label,
randomized, controlled trial performed to test the efﬁcacy of an
oral administration of n 3 PUFA (1g daily) and vitamin E on
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morbidity and mortality in 11,323 Italian patients with recent
(MI<3months; Gruppo Italiano per lo Studio della Soprav-
vivenza nell’Infarto miocardico, 1999). After 3.5years of follow-
up, n 3 PUFA therapy signiﬁcantly reduced the ﬁrst combined,
primary endpoint (death, non-fatal myocardial, and non-fatal
stroke) by 15% (95% conﬁdence interval, CI: 3–27, P D0.02) as
well as the co-primary endpoint (cardiovascular death plus non-
fatalMIplusnon-fatalstroke)by20%(95%CI:6–32,P D0.006)as
comparedtothecontrolgroup.Secondaryanalysesof thecompo-
nents of the primary endpoints showed that almost all the beneﬁt
observedinthecombinedendpointswasattributabletothereduc-
tion in fatal events: total mortality 20%, (95% CI: 6–23%); CV
death 30% (95% CI: 13–44%); CHD death 35% (95% CI: 16–
49%); and SCD 44% (95% CI: 24–60%). An intention-to-treat
analysis of GISSI-Prevenzione, adjusted for interaction between
treatments, was aimed at assessing the time course of beneﬁt on
fatal events. It showed an early divergence of the survival curves
forn 3PUFAsandcontrolgroupsafterrandomization,withtotal
mortality being signiﬁcantly lowered after only 3months of treat-
ment (RR 0.59, 95% CI: 0.36–0.97; P D0.037; Marchioli et al.,
2002). Likewise, the reduction in risk of SCD was already sta-
tistically signiﬁcant at 4months (RR 0.47; 95% CI: 0.219–0.995;
P D0.048). A similarly signiﬁcant, although delayed, pattern was
observed for CV, cardiac, and CHD deaths after 6–8months of
treatment.Inagreementwithpreviousevidencecomingfromboth
experimental and human studies,such ﬁndings suggested that the
early beneﬁts of n 3 PUFA may be due to their antiarrhythmic
activity (McLennan et al., 1992, 1993; Kang and Leaf, 1994, 1995,
1996;Kangetal.,1995;Sellmayeretal.,1995;Siscovicketal.,1995;
Xiaoetal.,1995,1997,1998;Christensenetal.,1997;Billmanetal.,
1999).
GISSI-Prevenzionetrialhadseveralstrengths.Itwasadequately
sized (the largest prospective controlled trial that investigated the
effect of a dietary-derived drug on CV events) in a population
of patients at high-risk of arrhythmia, with a reliable statistical
power to show that n 3 PUFA could decrease hard endpoints
of morbidity and mortality in a clinically and statistically signif-
icant manner. As to clinical relevance, it is worth noting that for
every 1000 post-MI patients treated for 1year with 1g daily of
n 3 PUFA, 5.7 lives were saved. Such protective effect with n 3
PUFA treatment observed in GISSI-Prevenzione is comparable in
the magnitude to the results of other drugs which are now con-
sidered therapeutic cornerstone in cardiovascular prevention. For
instance, in the LIPID trial, 5.2 lives could be saved treating with
pravastatinfor1year1000patientswithhypercholesterolemiaand
CHD(TheLong-TermInterventionwithPravastatininIschaemic
Disease (LIPID) Study Group, 1998). Although some changes in
the management of post-MI patients occurring over years have
to be considered, many aspects of GISSI-Prevenzione are reassur-
ing as to the transferability of the results to clinical practice for
post-MI patients,: (a) the trial was very large and performed in
the framework of a “usual care” clinical setting, (b) it was car-
ried out in a country-wide network of hospitals within the Italian
national public health service, and (c) had a pragmatic design
aimed at not interfering with daily clinical practice. It might be
also argued that in populations at high CV risk, such as those
with a western lifestyle, n 3 PUFA might have greater beneﬁt
than in the Italian population, known to be at low risk for CHD
mainly for the Mediterranean dietary habits (Marckmann and
Gronbaek, 1999). The beneﬁt of n 3 PUFA treatment can be
considered as additive to those of recommended pharmacological
treatments and lifestyle interventions. Indeed,patients enrolled in
GISSI-Prevenzione received n 3 PUFA treatment on the top of
preventive pharmacological treatments, including aspirin, beta-
blockers, angiotensin-converting enzyme (ACE) inhibitors and
cholesterol-lowering drugs, as well as of lifestyle interventions
leading at the end of the trial to a positive modiﬁcation of dietary
habits with increase of the (already relatively high) intake of olive
oil, fruit, vegetables, and ﬁsh (Barzi et al., 2003).
Recent randomized clinical trials did not conﬁrm the antiar-
rhythmic effect of n 3 PUFA. The Japan EPA Lipid Intervention
Study (JELIS; Yokoyama et al., 2007) was a large scale trial con-
ductedin18,000hypercholesterolemicJapanesepatientswhowere
randomized to n 3 PUFA treatment (1.8g/day) in combination
withstatinvs.statinalone.Afterameanfollow-upof 4.6years,the
patients in the n 3 PUFA group experienced a reduction of 19%
of CHDevents.Thebeneﬁtof n 3PUFAwaslimitedtonon-fatal
CHDevents,particularlyunstableangina,whilsttheeffectonfatal
eventswasnotsigniﬁcant,particularlyonSCD.Suchapparentlack
of theantiarrhythmiceffectinthispopulationof patientscouldbe
relatedtosomespeciﬁcaspectsof JELIS.Firstly,theassumptionof
reaching a statistical power of 80% for detecting a relative reduc-
tionof 25%intheprimaryendpointwasrespected,buttherateof
SCD (i.e.,a secondary outcome measure) in the JELIS population
was extremely low. Only 35 of the 18,645 participants (0.19%) in
JELIS experienced a SCD during 5years of follow-up. As a result
the study lacked sufﬁcient power, to detect an effect on mortality
in general and speciﬁcally on SCD (statistical power of 13, 7, and
5% to detect a relative reduction of 30, 20, and 10% of the risk in
SCD, respectively, Table 1). Another relevant aspect of JELIS was
the administration of 1.8g daily of eicosapentaenoic acid (EPA)
onthetopof ahighdietaryintakeof n 3PUFA.Apooledanalysis
of prospective and randomized studies suggested the existence of
a dose-response curve for the antiarrhythmic effect of n 3 PUFA
onSCD,whichseemstohaveasteepslopeatmodestlevelsof n 3
PUFA intake (<750mg) and a plateau thereafter, higher doses of
n 3PUFAhavingbeenhypothesizednothavingfurtherbeneﬁcial
effectsonSCD(MozaffarianandRimm,2006).Becauseofthehigh
ﬁshintake(e.g.,median900mg/day)of Japanesepeople(Isoetal.,
2006),this“threshold”effect might play a role in the JELIS results,
e.g., by magnifying anti-atherosclerotic, anti-inﬂammatory, and
plaque stabilizing effects of the high daily supplement of n 3
PUFA (1800mg) while the beneﬁt on arrhythmic events was not
detectable due to the low rate of such events in this population.
Like in the case of JELIS, the lack of clinical beneﬁt reported in
a previous study evaluating the effect of 4g/day of n 3 PUFA,
compared to corn oil, in 300 post-MI patients (4–8days; Nilsen
et al., 2001), may be due to both a “threshold effect” as well as to
an insufﬁcient study power due to the low event rate observed in
the study.
In 2010 the results of the OMEGA trial have been published.
The study was a randomized, double-blind, placebo-controlled,
multicentre trial, testing the effect of n 3 PUFA (1000mg/day
for 12months) on the rate of SCD in 3851 patients with MI
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in the previous 3–14days (Rauch et al., 2006, 2010). Secondary
endpoints of OMEGA included total mortality and non-fatal
CV events. Also, OMEGA showed no difference in the incidence
of SCD between n 3 PUFA and placebo groups (1.5 vs. 1.5%;
P D0.84). No difference with regard to secondary endpoints was
found (total mortality 4.6 vs. 3.7%; P D0.18; major cerebrovas-
cular and CV events 10.4 vs. 8.8%; P D0.1; revascularization in
survivors 27.6 vs. 29.1%; P D0.34). Some methodological aspects
of the OMEGA trial deserve to be considered. It was assumed that
the proportion of SCD during the study should have been 44%
of total deaths, therefore resulting in a SCD rate of 3.5% in the
control group at the end of the study. The observed incidence of
SCD was lower (1.5% in both groups), i.e., less than the half of
the expected one, thus making the trial underpowered to detect
an antiarrhythmic effect of n 3 PUFA (Table 1). Another aspect
to be considered is the treatment of post-MI patients enrolled in
OMEGA Study. Acute revascularization was performed in 81%
of patients. Short- and long-term guideline-driven medication
was administered in the vast majority of patients:b-blockers,ACE
inhibitors/angiotensin receptor blockers (ARB), statins, acetylsal-
icylic acid, and clopidogrel were prescribed to 94, 91, 94, 95, and
88%ofpatients,respectively.Thelargeuseofguideline-basedther-
apy after MI may have contributed to the low rate of fatal events,
so reducing the room for improvement due to n 3 PUFA treat-
ment, and, on the other hand, may also reduce the transferability
of OMEGA results to the treatment of post-MI patients that, to
date,stillappearsubstantiallydifferentinclinicalpractice(Kotseva
et al., 2009a,b).
The results of Alpha Omega Trial have been published a few
weeks after the publication of OMEGA (Kromhout et al., 2010).
AlphaOmegawasamulticenter,double-blind,placebo-controlled
trial testing the effects of n-3 PUFA on the rate of cardiovas-
cular events among 4837 patients, 60 through 80years of age,
who have had a MI. Patients were randomly assigned to use for
40months one of four types of margarine enriched with marine
n 3 PUFA with a targeted additional daily intake of (a) 400mg
of a combination of EPA and docosahexaenoic acid (DHA); (b)
plant-derived n 3 PUFA, with a targeted additional daily intake
of 2gof alpha-linolenicacid(ALA);(c)marine(400mg/day)plus
plant-derived (2g/day) n 3 PUFA; (e) placebo. Neither marine-
nor plant-derived n 3 PUFA reduced the primary endpoint, i.e.,
the rate of major CV events, including fatal and non-fatal CV
events and cardiac interventions (hazard ratio, HR with EPA–
DHA,1.01;95% CI: 0.87–1.17;P D0.93; HR withALA,0.91;95%
CI:0.78–1.05;P D0.20). n 3 PUFA did not reduce the secondary
endpoints,including ventricular arrhythmia-related events (SCD,
fatal and non-fatal cardiac arrest, and placement of implantable
cardioverter–deﬁbrillators; HR with EPA–DHA, 0.90; 95% CI:
0.65–1.26; P D0.55; HR with ALA, 0.79; 95% CI: 0.79–1.19;
P D0.16). Alpha Omega was a factorial trial and therefore only
thetwo-wayanalysescomparingpatientswhoreceivedEPA–DHA
to those not receiving marine n 3 PUFA as well as comparing
patients who received ALA to those not receiving plant-derived
n 3 PUFA were published. In the former case,2404 patients with
ameandailysupplementationofEPA-DHAof400mgplusamean
daily supplementation of ALA of 1008mg was compared to 2433
patients with a mean daily supplementation of ALA of 984mg.
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In the latter case, 2409 patients with a mean daily supplementa-
tion of EPA-DHA of 201mg plus a mean daily supplementation
of ALA of 2000mg was compared to 2428 patients with a mean
daily supplementation of EPA-DHA of 196mg. In other words,
the effect of n 3 PUFA was not compared with a pure“placebo.”
The assessment of the effect of n 3 PUFA was likely to be biased
because all the patients were receiving n 3 PUFA and in the case
of marine n 3 PUFA the comparison was between two groups
receiving approximately a total of 1.4 vs. 1.0g of n 3 PUFA.
The administration of n 3 PUFA in all patients of the Alpha
Omega trial has made the results difﬁcult to interpret and might
have obscured the antiarrhythmic effect of n 3 PUFA if a thresh-
old for the antiarrhythmic effect truly exists (de Lorgeril et al.,
1994; Leaf, 1999; Zatonski et al., 2008). More recently the results
of SU.FOL.OM3 study have been published (Galan et al., 2010).
Among 1863 patients with CHD, neither a treatment with n 3
PUFA (600mg/day), nor treatment with B vitamins was associ-
ated with a signiﬁcant effect on the occurrence of hard coronary
events,acompositeendpointincludingsuddendeath,afteramean
follow-upof 4.21.0years.Noinformationonsuddendeathwas
provided in this study.
HEART FAILURE
The GISSI-Prevenzione results showed that systolic dysfunction
was associated with elevated risk of SCD and with a consistent
beneﬁt from n 3 PUFA (Macchia et al., 2005). This was the
core hypothesis of the GISSI-HF Trial, a randomized, placebo-
controlled trial investigating the efﬁcacy of n 3 PUFA (850–
882mg EPA and DHA daily as ethyl ester compared to placebo)
in 6975 patients who had clinical evidence of HF, classiﬁed as
NYHA class II–IV, followed for a median of 3.9years (Tavazzi
et al., 2004, 2008). Statistically signiﬁcant risk reductions in the
two co-primary endpoints were observed in n 3 PUFA treated
patients: 9% (adjusted HR 0.91; 95% CI: 0.833–0.998; P D0.041)
and 8% (adjusted HR 0.92; 95% CI: 0.849–0.999; P D0.009) for
mortality and mortality plus admission to hospital for CV rea-
son, respectively (Table 2). It might be argued that the beneﬁt
showed by n 3 PUFA in HF patients is only marginal, being
modestastheamountof relativeriskreductionwasmodest.Actu-
ally, due to the high mortality and hospitalization rates in HF
patients, the relative risk reduction observed in GISSI-HF can be
translated into an absolute beneﬁt of 18 deaths avoided and 17
prevented CV hospitalizations for every 1000 patients treated for
3.9years with n 3 PUFA,i.e.,a not trivial beneﬁt as compared to
statins and ACE-inhibitors in high-risk populations (Yusuf et al.,
2000; Heart Protection Study Collaborative Group, 2002). The
main study results were consistent with those of the secondary
analyses,whichwerepredeﬁnedinthestudyprotocol,for(a)base-
line characteristics,(b) secondary outcomes,and (c) per-protocol
analysis in the 4994 patients who were compliant to experimen-
tal treatments. Worsening of HF and presumed arrhythmic death
accounted for 62% of all deaths and were lower in the n 3 PUFA
as compared to placebo group. Almost half of the absolute reduc-
tion of risk of death due to n 3 PUFA treatment was attributable
to the reduction of ventricular arrhythmias (mortality: 0.9% out
of 1.8%; ﬁrst CV hospitalization: 1.0% out of 1.7%). Moreover,
the rate of total major ventricular arrhythmias, deﬁned as the
occurrence of arrhythmic death or hospitalization due to ven-
tricular arrhythmias,was signiﬁcantly reduced early after the start
of treatment in the 3 PUFA group (Marchioli et al., submitted).
These ﬁndings support the idea that also in the clinical setting of
HF n 3 PUFA may exert their antiarrhythmic effect. In addition,
the beneﬁt in both co-primary endpoints (mortality and hospi-
talization) suggests that n 3 PUFA might positively affect the
pathophysiologic mechanisms leading to the progression of HF
(Marchiolietal.,2009;Ghioetal.,2010).GISSI-HFTrialhadsome
weaknesses and limitations. The patients enrolled in the GISSI-
HF trial were already treated with guideline-based therapies for
HF, so the beneﬁt of n 3 PUFA can be considered as additive
to the one determined by recommended treatments. Moreover,
GISSI-HF trial adopted a pragmatic strategy, representing what
happensinreal-worldsettingsof clinicalpractice.Thisassuresthe
transferability of the GISSI-HF results to all patients with HF and
suggest to not consider a limitation the apparent high percentages
of patients who were not fully compliant with experimental treat-
ments(bytheendof thestudy28.7%inthen 3PUFAgroupand
29.6% in the placebo group). Although the observed beneﬁt was
lowerthanexpected,itiscomparabletotheoneobtainedbytheuse
of chronic preventive treatments in other clinical settings (Yusuf
et al., 2000; Heart Protection Study Collaborative Group, 2002).
Ontheotherside,thehighpercentageof fullytreatedpatientsmay
haveleftlimitedroomtofurtherimprovement.Thelownumberof
patients with preserved left ventricular ejection fraction (<10%)
may be partially considered as a limitation since it precluded to
perform a reliable assessment of the effect of n 3 PUFA in this
subgroup of patients.
PATIENTS WITH IMPLANTABLE CARDIOVERTER
DEFIBRILLATOR
Few studies evaluated the antiarrhythmic effect of n 3 PUFA in
patients with ICD,reporting mixed results. Two hundred patients
with a recent episode of sustained ventricular tachycardia (VT) or
ventricular ﬁbrillation (VF) and implanted ICD were randomly
assignedtoreceiven 3PUFA,1.8g/day,orplacebointrialbyRaitt
etal.(2005)Atamedianfollow-upof 718days,n 3PUFAdidnot
prevent episodes of VT or VF. Overall, n 3 PUFA treatment was
associated with a trend toward a higher incidence of the primary
endpoint (time to ICD therapy forVT/VF;P D0.19),a signiﬁcant
increased rate of recurrent episodes of VT/VF (P <0.001) and,
in patients with VT as the qualifying entry rhythm, a signiﬁcant
increase in the primary endpoint (PD0.007).
Oneyearafterthisﬁrsttrial,theresultsofTheStudyonOmega-
3 Fatty acids and ventricular Arrhythmia (SOFA) have been pub-
lished (Brouwer et al., 2006). The SOFA trial was a randomized,
parallel, placebo-controlled, double-blind study evaluating the
effect of n 3 PUFA 2g/day for a median period of 356days, on
appropriate ICD intervention for VT or VF, or all-cause death
in 546 patients with ICD and prior documented malignant VT
or VF. No statistically signiﬁcant protective effect in n 3 PUFA
group was shown (HR 0.86; 95% CI: 0.64–1.16; PD0.33).
Astotheresultsof thesetwotrials,someaspectsof studydesign
have to be considered. The ﬁrst point is the type of population
enrolled in these studies. Approximately 23% of patients in the
trial of Raitt et al. (2005), and the 30% in SOFA had no history
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of CHD. The best evidence for the antiarrhythmic action of n 3
PUFA has been produced by experimental work performed in
ischemia-mediated animal models and in clinical trials carried
out in post-MI patients,in which ischemia-triggered arrhythmias
may be predominant. Consequently, it has been hypothesize that
n–3 PUFA may have a more favorable effect in patients in whom
the speciﬁc clinical setting and underlying arrhythmogenic mech-
anisms of initiation and propagation may be more susceptible to
the antiarrhythmic effects of n–3 PUFA (Leaf et al., 2003). The
second aspect is the primary endpoint used in ICD trials, i.e.,
VT or VF. It certainly may address the inﬂuence of n–3 PUFA
on the risk of ventricular arrhythmias, however it might not be
the ideal surrogate for the risk of sudden death. Although VT
may frequently degenerate in VF and consequently in a sudden
death, the spontaneous resolution of this ventricular arrhythmia
is not uncommon. We cannot exclude that the treatment with
n–3 PUFA might increase this favorable event, impossible to be
showed in patients with ICD because of the device intervention.
MoreovercaringphysicianswereallowedtoprogramICDasmore
appropriate for their patients, so it has to be taken into consider-
ation that this may represent a possible bias. Another aspect to be
considered is the statistical power of the two studies. The power
of trial by Raitt was signiﬁcantly weakened by the low event rate
observed in the placebo group as compared with the expected
one. In addition,the observed reduction of events was lower than
expected (Table 3). The total event rate of the primary endpoint
observedinSOFA(33%)wasclosetotheexpectedone(35%),but
the observed efﬁcacy of n–3 PUFA was lower than the expected
one that was used for sample size calculation. Accordingly, SOFA
had a 69% power to detect a 30% event reduction, so it is not
surprising that this study did not detect a signiﬁcant reduction in
the primary endpoint (Table 3).
Atvariancewiththesetwostudies,intheFAATstudy(Leafetal.,
2005) the administration of 2.6g/day of n–3 PUFA vs. placebo in
402 patients at high-risk for fatal ventricular arrhythmias showed
a trend toward a reduction of the primary endpoint (risk reduc-
tion of  28% of the time to the ﬁrst ICD event for VT or VF, or
death from any cause; P D0.057). Although the choice to include
all-cause death in the primary endpoint might be criticized,when
probable and deﬁnite episodes of VT orVF were used as outcome
measure,a statically signiﬁcant relative risk reduction of 31% was
obtained (P D0.033; Leaf et al., 2005).
Two meta-analyses of data collected in these three trials did
not support a protective effect of n 3 PUFA on cardiac arrhyth-
mias. The ﬁrst meta-analysis showed a signiﬁcant heterogeneity
between trials, and no effect of n 3 PUFA on the relative risk of
ICD discharge (RR 0.93; 95% CI: 0.70–1.24; Jenkins et al., 2008).
The second meta-analysis, conﬁrmed the existence of a consider-
able heterogeneity between the trials, and showed no convincing
protective effect of n 3 PUFA on time to ﬁrst conﬁrmed VF or
VT combined with death (RR 0.90; 95% CI: 0.67–1.22), although
the HR for the subgroup of patients with coronary artery disease
at baseline tended toward a protective effect (RR 0.79; 95% CI:
0.60–1.06; Brouwer et al., 2009).
The results of a GISSI-HF sub-study assessing the antiarrhyth-
mic effect of n 3 PUFA in 566 patients with HF enrolled who
had received an ICD for secondary or primary prevention of VF
or VT have been recently published (Finzi et al., 2011). The pri-
maryendpoint(deﬁnedastimetoﬁrstappropriateICDdischarge
for VT/VF; adjusted HRD0.80, 95% CI: 0.59–1.09, P D0.152),
and the number of ICD discharges were not signiﬁcantly altered
(P D0.30) by n 3 PUFA treatment.
Themeta-analysisof thesefourtrialsonn 3PUFAinpatients
withimplantedICDdidnotdemonstrateasigniﬁcantantiarrhyth-
mic effect of n 3 PUFA (OR 0.82; 95% CI: 0.67–1.01; P D0.06;
Figure 1).
PATIENTS AT RISK OF SUPRAVENTRICULAR
TACHYARRHYTHMIAS
Althoughresultsof observationalstudiessuggestedpositiveeffects
of n 3 PUFA in reducing the number of episodes as well as
the burden of atrial tachyarrhythmia (Biscione et al., 2005), ran-
domized control studies showed discrepant results (Table 4). An
open-label, prospective, randomized, controlled trial with par-
allel groups, tested the effect of 2g/day of n 3 PUFA on the
development of AF in the postoperative period in 160 patients
undergoing coronary artery by-pass grafting (CABG; Calo et al.,
2005). Its results showed that n 3 PUFA administration before
and during hospitalization substantially reduced the incidence of
postoperativeAF by 54.4% and was associated with a shorter hos-
pital stay as compared the control group. In 199 patients with
persistent AF treated with amiodarone and a renin-angiotensin-
aldosterone system inhibitor, the addition of n 3 PUFAs 2g/day
improved the probability of the maintenance of sinus rhythm
at 1year after direct current cardioversion (Nodari et al., 2011).
At variance with the previous study, a prospective, randomized,
double-blind,placebo-controlled,parallel-group multicenter trial
involving 663 outpatient participants with previous conﬁrmed
symptomatic paroxysmal (n D542) or persistent (n D121) AF
reported no difference between treatment groups (n 3 PUFA
8g/day or placebo for the ﬁrst 7days; n 3 PUFA 4g/day or
placebo thereafter through week 24) for recurrence of symp-
tomatic AF in the paroxystic AF stratum (HR, 1.15; 95% CI:
0.90–1.46; P D0.26), in the persistent AF stratum (HR, 1.64;95%
CI: 0.92–2.92; P D0.09), and in both strata combined (HR, 1.22;
95% CI: 0.98–1.52; P D0.08; Kowey et al., 2010).
A recent systematic review and meta-analysis of published
randomized trial regarding n 3 PUFA supplementation for AF
prevention on 1955 patients showed a signiﬁcant heterogeneity
among the studies [P D0.002, I(2)D65.0%] and did not ﬁnd
a signiﬁcant reduction in the risk for AF (OR 0.81, 95% CI:
0.57–1.15; P D0.24; Liu et al., 2011).
The discrepant results on the beneﬁt of n 3 PUFA in pre-
venting supraventricular tachyarrhythmia in the above discussed
trials may be due to several reasons. The role of several patient
characteristics were probably underestimated.
Left atrial dimension, AF duration, recurrent episodes of AF,
whichreducedthepossibilitiesofrestoreormaintainastablesinus
rhythm(Suzukietal.,2011;Pistersetal.,2012),werenorincluded
among inclusion criteria neither in subgroup analysis in all but
one of the studies. Nodari et al. (2011) showed that the main cor-
relates of AF recurrence were,other than n 3 PUFA,the duration
ofAFbeforerandomization,leftatrialdimension,andleftventric-
ular ejection fraction, suggesting that atrial remodeling may play
www.frontiersin.org June 2012 | Volume 3 | Article 202 | 7Marchioli and Levantesi Randomized clinical trials on n 3 PUFA
T
a
b
l
e
3
|
R
e
c
e
n
t
l
a
r
g
e
c
l
i
n
i
c
a
l
t
r
i
a
l
s
o
n
t
h
e
a
n
t
i
a
r
r
h
y
t
h
m
i
c
e
f
f
e
c
t
s
o
f
n
-
3
P
U
F
A
i
n
p
a
t
i
e
n
t
s
w
i
t
h
I
C
D
.
S
t
u
d
y
P
a
t
i
e
n
t
s
N
u
m
b
e
r
T
r
e
a
t
m
e
n
t
d
a
i
l
y
d
o
s
e
C
o
n
t
r
o
l
F
o
l
l
o
w
-
u
p
E
n
d
p
o
i
n
t
s
E
v
e
n
t
s
(
%
)
c
o
n
t
r
o
l
g
o
u
p
R
R
(
9
5
%
C
I
)
S
t
u
d
y
p
o
w
e
r
f
o
r
3
0
%
R
R
R
2
0
%
R
R
R
1
5
%
R
R
R
L
e
a
f
e
t
a
l
.
(
2
0
0
5
)
S
u
b
j
e
c
t
s
w
i
t
h
a
n
I
C
D
b
e
c
a
u
s
e
o
f
a
h
i
s
t
o
r
y
o
f
c
a
r
d
i
a
c
a
r
r
e
s
t
,
s
u
s
t
a
i
n
e
d
V
T
,
o
r
s
y
n
c
o
p
e
w
i
t
h
i
n
d
u
c
i
b
l
e
,
s
u
s
t
a
i
n
e
d
V
T
o
r
V
F
d
u
r
i
n
g
e
l
e
c
t
r
o
p
h
y
s
i
o
l
o
g
i
c
s
t
u
d
i
e
s
.
4
0
2
n
 
3
P
U
F
A
4
.
0
g
/
d
a
y
(
t
o
t
a
l
d
o
s
e
o
f
E
P
A
p
l
u
s
D
H
A
o
f
2
.
6
g
;
n
D
2
0
0
)
O
l
i
v
e
o
i
l
(
n
D
2
0
2
)
1
2
m
o
n
t
h
s
F
i
r
s
t
I
C
D
e
v
e
n
t
f
o
r
V
T
o
r
V
F
c
o
n
ﬁ
r
m
e
d
b
y
s
t
o
r
e
d
e
l
e
c
t
r
o
g
r
a
m
s
o
r
d
e
a
t
h
f
r
o
m
a
n
y
c
a
u
s
e
7
8
(
3
9
)
0
.
6
7
(
0
.
4
7
–
0
.
9
5
)
†
6
6
3
3
2
0
R
a
i
t
t
e
t
a
l
.
(
2
0
0
5
)
P
a
t
i
e
n
t
s
w
i
t
h
a
n
I
C
D
a
n
d
a
r
e
c
e
n
t
e
p
i
s
o
d
e
o
f
s
u
s
t
a
i
n
e
d
V
T
o
r
V
F
2
0
0
F
i
s
h
o
i
l
1
.
8
g
/
d
a
y
(
c
o
n
s
i
s
t
i
n
g
o
f
4
2
%
E
P
A
)
a
n
d
3
0
%
D
H
A
;
n
D
1
0
0
)
O
l
i
v
e
o
i
l
(
7
3
%
o
l
e
i
c
a
c
i
d
,
1
2
%
p
a
l
m
i
t
i
c
a
c
i
d
,
0
%
E
P
A
/
D
H
A
;
n
D
1
0
0
)
7
1
8
d
a
y
s
F
i
r
s
t
e
p
i
s
o
d
e
o
f
V
T
/
V
F
l
e
a
d
i
n
g
t
o
I
C
D
t
h
e
r
a
p
y
6
m
o
n
t
h
s
6
m
o
n
t
h
s
3
6
(
S
E
5
%
)
3
2
1
5
1
0
1
2
m
o
n
t
h
s
1
2
m
o
n
t
h
s
4
1
(
5
%
)
3
9
1
8
1
1
2
4
m
o
n
t
h
s
2
4
m
o
n
t
h
s
5
9
(
5
%
)
1
.
2
6
(
0
.
8
8
–
1
.
8
6
)
6
6
3
3
2
0
S
O
F
A
(
B
r
o
u
w
e
r
e
t
a
l
.
,
2
0
0
6
)
S
u
b
j
e
c
t
s
w
h
o
h
a
d
e
i
t
h
e
r
a
n
I
C
D
o
r
w
e
r
e
a
b
o
u
t
t
o
r
e
c
e
i
v
e
o
n
e
a
n
d
a
t
l
e
a
s
t
1
c
o
n
ﬁ
r
m
e
d
V
T
o
r
V
F
i
n
t
h
e
p
r
e
c
e
d
i
n
g
y
e
a
r
5
4
6
F
i
s
h
o
i
l
2
g
/
d
a
y
(
f
o
u
r
c
a
p
s
u
l
e
s
c
o
n
t
a
i
n
i
n
g
9
6
1
m
g
o
f
o
m
e
g
a
-
3
P
U
F
A
s
(
4
6
4
m
g
E
P
A
,
3
3
5
m
g
D
H
A
,
a
n
d
1
6
2
m
g
o
t
h
e
r
o
m
e
g
a
-
3
P
U
F
A
s
;
n
D
2
7
3
)
P
l
a
c
e
b
o
c
o
n
t
a
i
n
i
n
g
2
g
o
f
h
i
g
h
-
o
l
e
i
c
a
c
i
d
s
u
n
ﬂ
o
w
e
r
o
i
l
.
(
n
D
2
7
3
)
3
5
6
d
a
y
s
S
u
s
t
a
i
n
e
d
I
C
D
i
n
t
e
r
v
e
n
t
i
o
n
o
r
d
e
a
t
h
f
r
o
m
a
n
y
c
a
u
s
e
9
0
(
3
3
)
0
.
8
6
(
0
.
6
4
–
1
.
1
6
)
6
9
3
6
2
1
D
e
a
t
h
f
r
o
m
a
n
y
c
a
u
s
e
1
4
(
5
)
1
0
5
4
D
e
a
t
h
f
o
r
C
a
r
d
i
a
c
c
a
u
s
e
1
3
(
5
)
1
0
5
4
I
C
D
i
n
t
e
r
v
e
n
t
i
o
n
f
o
r
ﬁ
r
s
t
e
v
e
n
t
8
1
(
3
0
)
0
.
8
9
(
0
.
6
5
–
1
.
2
2
)
6
4
3
2
1
9
M
I
3
(
1
)
<
1
<
1
<
1
F
i
n
z
i
e
t
a
l
.
(
2
0
1
1
)
P
a
t
i
e
n
t
s
w
i
t
h
H
F
a
n
d
a
n
I
C
D
f
o
r
s
e
c
o
n
d
a
r
y
o
r
p
r
i
m
a
r
y
p
r
e
v
e
n
t
i
o
n
o
f
V
F
o
r
V
T
5
6
6
n
 
3
P
U
F
A
1
g
/
d
a
y
(
8
5
0
–
8
8
2
m
g
E
P
A
a
n
d
D
H
A
i
n
t
h
e
a
v
e
r
a
g
e
r
a
t
i
o
o
f
1
:
1
·
2
;
n
D
2
7
8
)
P
l
a
c
e
b
o
(
n
D
2
8
8
)
9
2
8
d
a
y
s
(
m
e
d
i
a
n
)
A
p
p
r
o
p
r
i
a
t
e
I
C
D
i
n
t
e
r
v
e
n
t
i
o
n
f
o
r
m
a
j
o
r
a
r
r
h
y
t
h
m
i
a
s
8
2
(
2
8
.
5
)
0
.
8
0
(
0
.
5
9
–
1
.
0
9
)
5
4
3
6
2
1
V
T
,
v
e
n
t
r
i
c
u
l
a
r
t
a
c
h
y
c
a
r
d
i
a
;
V
F
,
v
e
n
t
r
i
c
u
l
a
r
ﬁ
b
r
i
l
l
a
t
i
o
n
;
E
P
A
,
e
i
c
o
s
a
p
e
n
t
a
e
n
o
i
c
a
c
i
d
;
D
H
A
,
d
o
c
o
s
a
h
e
x
a
e
n
o
i
c
a
c
i
d
;
p
r
i
m
a
r
y
e
n
d
p
o
i
n
t
s
i
n
b
o
l
d
;
R
R
,
r
e
l
a
t
i
v
e
r
i
s
k
;
C
I
,
c
o
n
ﬁ
d
e
n
c
e
r
i
s
k
;
R
R
R
,
r
e
l
a
t
i
v
e
r
i
s
k
r
e
d
u
c
t
i
o
n
;
†
P
<
0
.
0
5
.
Frontiers in Physiology | Cardiac Electrophysiology June 2012 | Volume 3 | Article 202 | 8Marchioli and Levantesi Randomized clinical trials on n 3 PUFA
T
a
b
l
e
4
|
R
e
c
e
n
t
l
a
r
g
e
c
l
i
n
i
c
a
l
t
r
i
a
l
s
o
n
t
h
e
a
n
t
i
a
r
r
h
y
t
h
m
i
c
e
f
f
e
c
t
s
o
f
n
-
3
P
U
F
A
i
n
p
a
t
i
e
n
t
s
w
i
t
h
A
F
.
S
t
u
d
y
P
a
t
i
e
n
t
s
N
u
m
b
e
r
T
r
e
a
t
m
e
n
t
d
a
i
l
y
d
o
s
e
C
o
n
t
r
o
l
F
o
l
l
o
w
-
u
p
E
n
d
p
o
i
n
t
s
E
v
e
n
t
s
(
%
)
c
o
n
t
r
o
l
g
o
u
p
R
R
(
9
5
%
C
I
)
S
t
u
d
y
p
o
w
e
r
f
o
r
3
0
%
R
R
R
2
0
%
R
R
R
1
5
%
R
R
R
C
a
l
o
e
t
a
l
.
(
2
0
0
5
)
P
a
t
i
e
n
t
s
u
n
d
e
r
g
o
i
n
g
C
A
B
G
1
6
0
n
 
3
P
U
F
A
2
g
/
d
a
y
(
8
5
0
–
8
8
2
m
g
E
P
A
a
n
d
D
H
A
i
n
t
h
e
a
v
e
r
a
g
e
r
a
t
i
o
o
f
E
P
A
/
D
H
A
1
:
2
i
n
e
a
c
h
1
-
g
c
a
p
s
u
l
e
;
n
D
7
9
)
U
s
u
a
l
c
a
r
e
(
n
D
8
1
)
D
a
y
s
8
.
2

2
.
6
c
7
.
3

2
.
1
t
O
c
c
u
r
r
e
n
c
e
o
f
A
F
2
7
(
3
3
.
3
)
0
.
3
2
(
0
.
1
0
–
0
.
9
8
)
†
2
3
1
1
7
H
o
s
p
i
t
a
l
l
e
n
g
t
h
o
f
s
t
a
y
8
.
2

2
.
6
d
a
y
s
K
o
w
e
y
e
t
a
l
.
(
2
0
1
0
)
S
u
b
j
e
c
t
s
w
i
t
h
a
c
o
n
ﬁ
r
m
e
d
d
i
a
g
n
o
s
i
s
o
f
s
y
m
p
t
o
m
a
t
i
c
p
a
r
o
x
y
s
m
a
l
A
F
6
6
3
(
5
2
7
p
a
r
o
x
y
s
-
m
a
l
A
F
;
1
1
8
p
e
r
s
i
s
t
e
n
t
A
F
)
n
 
3
P
U
F
A
4
g
/
d
a
y
(
a
p
p
r
o
x
i
m
a
t
e
l
y
4
6
5
m
g
o
f
E
P
A
a
n
d
3
7
5
m
g
o
f
D
H
A
i
n
e
a
c
h
1
-
g
c
a
p
s
u
l
e
)
.
(
n
D
3
3
2
;
2
5
8
p
a
r
o
x
A
F
;
6
4
p
e
r
s
A
F
)
C
o
r
n
o
i
l
a
p
p
r
o
x
i
-
m
a
t
e
l
y
8
g
/
d
a
y
(
n
D
2
6
9
;
3
3
1
p
a
r
o
x
A
F
;
5
4
p
e
r
s
A
F
)
6
m
o
n
t
h
s
F
i
r
s
t
r
e
c
u
r
r
e
n
c
e
o
f
s
y
m
p
t
o
m
a
t
i
c
A
F
o
r
ﬂ
u
t
t
e
r
1
2
9
(
4
8
)
1
.
1
5
(
0
.
9
0
–
1
.
4
6
)
9
1
5
7
3
5
I
n
d
e
p
e
n
d
e
n
t
a
n
a
l
y
s
i
s
a
1
2
9
(
4
7
)
1
.
1
9
(
0
.
9
3
–
1
.
3
5
)
9
0
5
5
3
4
F
i
r
s
t
r
e
c
u
r
r
e
n
c
e
o
f
s
y
m
p
t
o
m
a
t
i
c
A
F
o
r
ﬂ
u
t
t
e
r
b
1
3
6
(
4
9
)
1
.
1
5
(
0
.
9
1
–
1
.
4
5
)
9
2
5
8
3
6
F
i
r
s
t
r
e
c
u
r
r
e
n
c
e
o
f
s
y
m
p
t
o
m
a
t
i
c
A
F
(
e
x
c
l
u
s
i
v
e
o
f
ﬂ
u
t
t
e
r
)
1
2
6
(
4
7
)
1
.
1
7
(
0
.
9
1
–
1
.
4
9
)
9
0
5
7
3
5
I
n
d
e
p
e
n
d
e
n
t
a
n
a
l
y
s
i
s
a
1
2
6
(
4
6
)
1
.
2
2
(
0
.
9
5
–
1
.
5
6
)
8
9
5
4
3
3
F
i
r
s
t
r
e
c
u
r
r
e
n
c
e
o
f
s
y
m
p
t
o
m
a
t
i
c
o
r
a
s
y
m
p
t
o
m
a
t
i
c
A
F
o
r
ﬂ
u
t
t
e
r
1
4
9
(
5
5
)
1
.
1
2
(
0
.
8
9
–
1
.
4
0
)
9
6
6
8
4
4
I
n
d
e
p
e
n
d
e
n
t
a
n
a
l
y
s
i
s
a
1
5
2
(
5
5
)
1
.
1
3
(
0
.
9
0
–
1
.
4
2
)
9
6
6
8
4
4
F
i
r
s
t
r
e
c
u
r
r
e
n
c
e
o
f
s
y
m
p
t
o
m
a
t
i
c
o
r
a
s
y
m
p
t
o
m
a
t
i
c
A
F
(
e
x
c
l
u
s
i
v
e
o
f
ﬂ
u
t
t
e
r
)
1
4
6
(
5
4
)
1
.
1
4
(
0
.
9
0
–
1
.
4
3
)
9
6
6
7
4
3
I
n
d
e
p
e
n
d
e
n
t
a
n
a
l
y
s
i
s
a
1
4
9
(
5
4
)
1
.
1
5
(
0
.
9
2
–
1
.
4
5
)
9
6
6
7
4
3
(
C
o
n
t
i
n
u
e
d
)
www.frontiersin.org June 2012 | Volume 3 | Article 202 | 9Marchioli and Levantesi Randomized clinical trials on n 3 PUFA
T
a
b
l
e
4
|
C
o
n
t
i
n
u
e
d
S
t
u
d
y
P
a
t
i
e
n
t
s
N
u
m
b
e
r
T
r
e
a
t
m
e
n
t
d
a
i
l
y
d
o
s
e
C
o
n
t
r
o
l
F
o
l
l
o
w
-
u
p
E
n
d
p
o
i
n
t
s
E
v
e
n
t
s
(
%
)
c
o
n
t
r
o
l
g
o
u
p
R
R
(
9
5
%
C
I
)
S
t
u
d
y
p
o
w
e
r
f
o
r
3
0
%
R
R
R
2
0
%
R
R
R
1
5
%
R
R
R
N
o
d
a
r
i
e
t
a
l
.
(
2
0
1
1
)
P
e
r
s
i
s
t
e
n
t
A
F
l
a
s
t
i
n
g

1
m
o
n
t
h
a
n
d
c
o
n
ﬁ
r
m
e
d
b
y
E
C
G
H
o
l
t
e
r
m
o
n
i
t
o
r
i
n
g
a
n
d
h
i
s
t
o
r
y
o
f
a
t
l
e
a
s
t
o
n
e
r
e
l
a
p
s
e
a
f
t
e
r
p
r
e
v
i
o
u
s
s
u
c
c
e
s
s
f
u
l
c
a
r
d
i
o
v
e
r
s
i
o
n
1
9
9
n
 
3
P
U
F
A
2
g
/
d
a
y
(
8
5
0
–
8
8
2
m
g
o
f
E
P
A
a
n
d
D
H
A
i
n
t
h
e
a
v
e
r
a
g
e
r
a
t
i
o
o
f
E
P
A
/
D
H
A
o
f
1
.
2
i
n
e
a
c
h
1
.
0
-
g
c
a
p
s
u
l
e
(
a
l
l
o
w
e
d
r
a
n
g
e
,
0
.
9
–
1
.
5
;
n
D
1
0
0
)
O
l
i
v
e
o
i
l
2
g
/
d
a
y
(
n
D
9
9
)
1
y
e
a
r
P
r
o
b
a
b
i
l
i
t
y
o
f
m
a
i
n
t
e
n
a
n
c
e
o
f
s
i
n
u
s
r
h
y
t
h
m
5
6
/
9
9
(
5
6
.
6
)
0
.
6
2
(
0
.
5
2
–
0
.
7
2
)
§
6
2
3
0
1
8
5
E
P
A
,
e
i
c
o
s
a
p
e
n
t
a
e
n
o
i
c
a
c
i
d
;
D
H
A
,
d
o
c
o
s
a
h
e
x
a
e
n
o
i
c
a
c
i
d
;
p
r
i
m
a
r
y
e
n
d
p
o
i
n
t
s
i
n
b
o
l
d
;
R
R
,
r
e
l
a
t
i
v
e
r
i
s
k
;
C
I
,
c
o
n
ﬁ
d
e
n
c
e
r
i
s
k
;
R
R
R
,
r
e
l
a
t
i
v
e
r
i
s
k
r
e
d
u
c
t
i
o
n
;
†
P
<
0
.
0
5
,
§
P
<
0
.
0
0
1
;
a
V
a
l
u
e
s
a
r
e
b
a
s
e
d
o
n
t
h
e
i
n
d
e
p
e
n
d
e
n
t
s
t
a
t
i
s
t
i
c
i
a
n
’
s
a
n
a
l
y
s
e
s
(
p
a
r
t
i
c
i
p
a
n
t
s
w
i
t
h
a
n
t
i
a
r
r
h
y
t
h
m
i
c
d
r
u
g
u
s
e
w
e
r
e
n
o
t
c
e
n
s
o
r
e
d
)
u
s
i
n
g
C
o
x
p
r
o
p
o
r
t
i
o
n
a
l
h
a
z
a
r
d
m
o
d
e
l
:
l
o
g
(
h
a
z
a
r
d
r
a
t
i
o
)
e
q
u
a
l
s
t
r
e
a
t
m
e
n
t
p
l
u
s
r
e
g
i
o
n
p
l
u
s
a
n
g
i
o
t
e
n
s
i
n
-
c
o
n
v
e
r
t
i
n
g
e
n
z
y
m
e
i
n
h
i
b
i
t
o
r
o
r
a
n
g
i
o
t
e
n
s
i
n
I
I
r
e
c
e
p
t
o
r
b
l
o
c
k
e
r
p
l
u
s
s
t
a
t
i
n
.
b
S
e
n
s
i
t
i
v
i
t
y
a
n
a
l
y
s
i
s
u
s
i
n
g
t
h
e
o
r
i
g
i
n
a
l
s
t
r
a
t
u
m
a
t
r
a
n
d
o
m
i
z
a
t
i
o
n
.
a role in this clinical setting. Similarly to the case of drugs inhibit-
ing renin-angiotensin system, clinical success in restoring sinus
rhythm is likely to be achievable only before the underlying atrial
remodeling may have gone too far to be reversed (Savelieva et al.,
2011). Baseline plasma levels of n 3 PUFA may have inﬂuenced
the antiarrhythmic effect of oral supplementation (Skuladottir
etal.,2011),andtheuseofnew-onset,postoperativeAFmaynotbe
theidealmodeltoassesstheeffectof n 3PUFAonnew-onsetAF.
To date, as Camm and Savelieva (2011) afﬁrmed in their edi-
torial comment to the Nodari’s article, the antiarrhythmic effect
of n 3 PUFA in AF has not been demonstrated in randomized
clinical trial. A large scale randomized controlled trial testing the
effect of n 3 PUFA on supraventricular arrhythmias in patients
undergoing to cardiac surgery is currently ongoing (Mozaffarian
et al., 2011). Its results will increase our knowledge on the antiar-
rhythmic effects as well as on tolerability of n 3 PUFA in this
clinical setting.
REVIEWS AND META-ANALYSES
The effect of n 3 PUFA on cardiovascular events and SCD has
been analyzed in some reviews and meta-analyses.
A Cochrane review (Hooper et al., 2004) and a meta-analysis
(Hooper et al., 2006) did not ﬁnd a beneﬁt of n 3 PUFA admin-
istration. The Cochrane review (Hooper et al., 2004), which
included 89 studies (48 randomized controlled studies and 41
cohort studies), found that n 3 PUFA did not cause a signiﬁ-
cant reduction in the risk of total mortality (RR 0.87; 95% CI:
0.73–1.03) or combined CV events (RR 0.95; 95% CI: 0.82–1.12).
Considerable debate was generated by the choice of inclusion
of the DART II (Burr et al., 2003) in the analysis, because of
various limitations of the study and the difﬁculties occurring dur-
ing its conduct (von Schacky et al., 2006; Graham et al., 2007;
von Schacky and Harris, 2007). After excluding DART II from
the Cochrane analysis, the reduction of total death became sta-
tistically signiﬁcant (RR 0.83; 95% CI: 0.75–0.91), although the
risk of CV events did not change (Hooper et al., 2004). More
recently a review, at variance with the previous ones, pooled the
effect on SCD of eight trials, comprising 20,997 patients, and
showed that the treatment with n 3 PUFA was able to signiﬁ-
cantly reduce the incidence of SCD (RR 0.43; 95% CI: 0.20–0.91)
in post-MI patients. In patients with angina the risk of SCD
was increased (RR 1.39; 95% CI: 1.01–1.92) and overall, n 3
PUFA had no effect on cardiac death and all-cause mortality (RR
0.71 and 0.77; 95% CI: 0.50–1.00 and 0.58–1.01, respectively;
Zhao et al., 2009). In 2010 a meta-analysis of 29 randomized
controlled trials, comprising 35.144 patients, showed that n 3
PUFA treatment was not associated with a statistically signiﬁ-
cant decreased mortality (RR 0.88; 95% CI: 0.64–1.03) although
the probability of some beneﬁts was high (0.93; Filion et al.,
2010). A recent meta-analysis, including 20.485 patients with a
history of CVD, showed that n 3 PUFA supplementation did
not reduce the risk of overall CV events (RR 0.99; 95% CI: 0.89–
1.09), all-cause mortality, SCD, MI, HF, or transient ischemic
attack and stroke (Kwak et al., 2012). About the results of this last
meta-analysis several aspects deserve to be considered, e.g., most
studies were very small, not designed to evaluate CV endpoints
and with a short follow-up, the methodological choice of using
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FIGURE 1 | Pooled analysis of the effect of n-3 PUFA on appropriate ICD intervention.
random-effects models in the primary analysis, and the exclu-
sion of two large open-label trials (Gruppo Italiano per lo Studio
dellaSopravvivenzanell’Infartomiocardico,1999;Yokoyamaetal.,
2007).
CONCLUSION
The evidence available to date seem to suggest n 3 PUFA having
an antiarrhythmic effects, but no ﬁrm conclusion can be drawn.
The stronger evidence on positive effects of n 3 PUFA in reduc-
ing SCD came from studies including patients with CHD. In
patients with symptomatic HF,n 3 PUFA seem to reduce signiﬁ-
cantlyventriculararrhythmiasandSCD.Sucheffectonventricular
arrhythmia has not been convincingly conﬁrmed so far by the
results of trials in carriers of an ICD, though the meta-analysis of
thestudiesinICDpatientsisverysuggestive.Ontheotherside,the
effectonrecurrent/new-onsetAFisstillcontroversial.Manyof the
clinical trials conducted so had not signiﬁcant results. The main
causeof this“failure”istheinadequatepowerof thestudiesdueto
either low rate of events or the overoptimistic expectations of the
beneﬁtofn 3PUFAusedforsamplesizecalculation.Serumbase-
line levels of n 3 PUFA and different doses may have contributed
to such results.
In conclusion, the still debated antiarrhythmic effect of n 3
PUFA needs to be investigated in larger and/or more efﬁcient
trials than those conducted so far. On this regard it is possible
that a more accurate selection of patients,e.g.,evaluating relevant
biological parameters and markers (type and length of AF, left
atrial dimensions, plasma and cellular n 3 PUFA levels, systemic
inﬂammatory status, or oxidative stress), a standardization in the
device programming in ICD patient populations, and a “realis-
tic” sample size calculation might answer some of the still open
question on the antiarrhythmic effect of n 3 PUFA.
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